NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology Inc (NASDAQ:KURA) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Kura Oncology.

Kura Oncology will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 equities research analysts have issued 12-month price targets for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's stock price to reach $26.83 in the next year. This suggests a possible upside of 113.0% from the stock's current price. View Analyst Price Targets for Kura Oncology.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

News coverage about KURA stock has trended negative on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kura Oncology earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Kura Oncology.

Kura Oncology saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,530,000 shares, an increase of 26.5% from the January 15th total of 2,000,000 shares. Based on an average trading volume of 293,700 shares, the days-to-cover ratio is currently 8.6 days. Currently, 6.2% of the shares of the company are short sold. View Kura Oncology's Current Options Chain.

Some companies that are related to Kura Oncology include Ra Pharmaceuticals (RARX), Synthorx (THOR), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Forty Seven (FTSV), Xencor (XNCR), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), Cambrex (CBM), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Tricida (TCDA) and Ligand Pharmaceuticals (LGND).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Agile Therapeutics (AGRX), Amarin (AMRN), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Aduro BioTech (ADRO), Advanced Micro Devices (AMD), Fate Therapeutics (FATE), vTv Therapeutics (VTVT), ACADIA Pharmaceuticals (ACAD) and Catalyst Pharmaceuticals (CPRX).

Kura Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), EcoR1 Capital LLC (9.36%), Victory Capital Management Inc. (5.26%), Victory Capital Management Inc. (5.24%), Eagle Asset Management Inc. (4.55%) and State Street Corp (2.34%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View Institutional Ownership Trends for Kura Oncology.

KURA stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Driehaus Capital Management LLC, State Street Corp, Man Group plc, SG Americas Securities LLC, Oak Ridge Investments LLC, UBS Group AG and Rafferty Asset Management LLC. View Insider Buying and Selling for Kura Oncology.

KURA stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EcoR1 Capital LLC, Point72 Asset Management L.P., WCM Investment Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., FMR LLC and Pathway Capital Management LP. View Insider Buying and Selling for Kura Oncology.

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KURA stock can currently be purchased for approximately $12.60.

Kura Oncology has a market capitalization of $570.91 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

The official website for Kura Oncology is http://www.kuraoncology.com/.

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]